Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Assets Average: 2021-2025

Historic Assets Average for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $14.5 million.

  • InMed Pharmaceuticals' Assets Average rose 29.85% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 29.85%. This contributed to the annual value of $13.7 million for FY2025, which is 5.68% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Assets Average stood at $14.5 million, which was up 16.42% from $12.4 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Assets Average high stood at $18.4 million for Q4 2021, and its period low was $8.9 million during Q1 2025.
  • In the last 3 years, InMed Pharmaceuticals' Assets Average had a median value of $12.6 million in 2024 and averaged $12.7 million.
  • Over the last 5 years, InMed Pharmaceuticals' Assets Average had its largest YoY gain of 29.85% in 2025, and its largest YoY loss of 37.86% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Assets Average (Quarterly) stood at $18.4 million in 2021, then dropped by 14.18% to $15.8 million in 2022, then declined by 16.92% to $13.1 million in 2023, then declined by 27.53% to $9.5 million in 2024, then increased by 29.85% to $14.5 million in 2025.
  • Its Assets Average stands at $14.5 million for Q3 2025, versus $12.4 million for Q2 2025 and $8.9 million for Q1 2025.